Hengrui's Remimazolam Tosilate for Injection Wins Approval for ICU Mechanical Ventilation Sedation

China's NMPA has approved a new indication for Hengrui Medicine's Class 1 innovative drug remimazolam tosilate for injection (brand name Ruibening) for sedation during mechanical ventilation in the ICU. The approval is based on two pivotal studies, HR7056-302 in short-term sedation and HR7056-206 in long-term sedation, both of which met their primary endpoints as expected.